Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
about
Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries.Risk of Long-Term Care Dependence for Dementia Patients is Associated with Type of Physician: An Analysis of German Health Claims Data for the Years 2006 to 2010.Differential diagnosis of neurodegenerative diseases using structural MRI dataLong-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.Update on the pharmacological treatment of Alzheimer's diseaseA European study investigating patterns of transition from home care towards institutional dementia care: the protocol of a RightTimePlaceCare studyMeasuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer's disease.Predictors of institutionalization of dementia patients in mild and moderate stages: a 4-year prospective analysis.Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's diseasePre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population.Factors related to continuous and discontinuous attendance at memory clinics.Practices in diagnosis, disclosure and pharmacotherapeutic management of dementia by general practitioners--a national survey.Inter-country exploration of factors associated with admission to long-term institutional dementia care: evidence from the RightTimePlaceCare study.Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease.Withdrawal of Antidementia Drugs in Older People: Who, When and How?Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.Could cholinesterase inhibitors be harmful over the long term?The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
P2860
Q30839132-E7EA0B8D-EC49-435A-B34B-54666B69F9BDQ30996681-A10CB4E3-A7F9-4086-871C-0317029D31ACQ31082974-4F0EEEAB-E5F4-4111-BED8-194F3D350911Q33790288-A425803F-7AA4-4CC6-99A7-88026473CB53Q33836947-FAF066AD-C889-4249-832A-51051BB3ECDFQ34136193-305D05CF-7D07-4DCE-9BAB-879214D76036Q36949519-096AFA80-0C62-4A92-8B8C-E812388C9A72Q37261204-37A66637-6218-4D47-ACEF-9B2036FC4111Q37350746-15FD26A9-E143-49D6-AA09-029843A3D469Q37708297-3E3A88C0-B735-4477-8DE0-56455910CF41Q38108761-8AF0BD8B-FFFE-4745-89E6-19538A9F462BQ38934118-06763E18-8F0C-4EC2-AE9D-D3255BFB7222Q39381334-02DEBD46-2AF3-4A83-A57E-C7FC5973F14FQ41079517-11E120B9-9ECD-42F8-9616-F8E95185B73FQ44281582-3F19DDEE-B3AE-47AA-9FB6-433FBC1F8ADCQ48167336-212CE792-04AD-4255-AF58-F4E11E82A7ABQ53323073-11DE89F2-C30D-43F8-AD26-972148E79C62Q53324826-5DDE10CA-CE9D-44AB-A6E3-251BBB684230Q57177786-0BB171F5-3C2D-4345-81C4-478CB04C9C97
P2860
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Treatment with galantamine and ...... thout cerebrovascular disease.
@en
Treatment with galantamine and ...... thout cerebrovascular disease.
@nl
type
label
Treatment with galantamine and ...... thout cerebrovascular disease.
@en
Treatment with galantamine and ...... thout cerebrovascular disease.
@nl
prefLabel
Treatment with galantamine and ...... thout cerebrovascular disease.
@en
Treatment with galantamine and ...... thout cerebrovascular disease.
@nl
P2093
P2860
P356
P1476
Treatment with galantamine and ...... thout cerebrovascular disease.
@en
P2093
Bart Van Baelen
Jean François Dartigues
Shane Kavanagh
Susanne Schwalen
Tuula Pirttila
P2860
P304
P356
10.1002/GPS.2141
P407
P577
2009-05-01T00:00:00Z